Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Ernstoff

Showing results (41-50 of 169) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II studyRonald Bukowski, Marc S Ernstoff, Martin E Gore, et al.
Journal of Extracellular Vesicles|December 7, 2019
Purity and yield of melanoma exosomes are dependent on isolation methodShin La Shu, Yunchen Yang, Cheryl L Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2010
A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survivalRichard J Barth, Dawn A Fisher, Paul K Wallace, et al.
World Journal of Oncology|June 23, 2023
Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor TherapyJoy Sarkar, Eduardo Cortes Gomez, Takaaki Oba, et al.
Journal of Immunological Methods|May 2, 2002
Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applicationsCheryl A Guyre, Jan L Fisher, Mary G Waugh, et al.
Oncology Reports|January 12, 2023
Targeting the secreted RGDKGE collagen fragment reduces PD‑L1 by a proteasome‑dependent mechanism and inhibits tumor growthJennifer M Caron, Xianghua Han, Christine W Lary, et al.
Medical Oncology (Northwood, London, England)|September 30, 2003
Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)Janice P Dutcher, Jason P Fine, Robert L Krigel, et al.
Journal for Immunotherapy of Cancer|April 23, 2020
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapyJared E Lopes, Jan L Fisher, Heather L Flick, et al.
Molecular Cancer Therapeutics|May 14, 2017
NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human TumorsClaire Godbersen, Tiffany A Coupet, Amelia M Huehls, et al.
Cancer Letters|June 9, 2009
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanomaEduardo Huarte, Jan Fisher, Mary Jo Turk, et al.
Pageof 17

Showing results (41-50 of 169) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II studyRonald Bukowski, Marc S Ernstoff, Martin E Gore, et al.
Journal of Extracellular Vesicles|December 7, 2019
Purity and yield of melanoma exosomes are dependent on isolation methodShin La Shu, Yunchen Yang, Cheryl L Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2010
A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survivalRichard J Barth, Dawn A Fisher, Paul K Wallace, et al.
World Journal of Oncology|June 23, 2023
Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor TherapyJoy Sarkar, Eduardo Cortes Gomez, Takaaki Oba, et al.
Journal of Immunological Methods|May 2, 2002
Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applicationsCheryl A Guyre, Jan L Fisher, Mary G Waugh, et al.
Oncology Reports|January 12, 2023
Targeting the secreted RGDKGE collagen fragment reduces PD‑L1 by a proteasome‑dependent mechanism and inhibits tumor growthJennifer M Caron, Xianghua Han, Christine W Lary, et al.
Medical Oncology (Northwood, London, England)|September 30, 2003
Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)Janice P Dutcher, Jason P Fine, Robert L Krigel, et al.
Journal for Immunotherapy of Cancer|April 23, 2020
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapyJared E Lopes, Jan L Fisher, Heather L Flick, et al.
Molecular Cancer Therapeutics|May 14, 2017
NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human TumorsClaire Godbersen, Tiffany A Coupet, Amelia M Huehls, et al.
Cancer Letters|June 9, 2009
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanomaEduardo Huarte, Jan Fisher, Mary Jo Turk, et al.
Pageof 17